Grant: Alliance Grants
University of Toronto
$65,500.00
Development of the Dominant Rotor Technology for Drug Discovery
FY 2021-22
Summary
This proposal leverages the recently developed technology aimed at conformation-activity studies and rarely visited conformations of complex rings. The primary focus is on macrocycles that are primarily composed of natural amino acid building blocks. While cyclic peptides have received a tremendous amount of attention over the years, their structures are not ideally suited for the development of biological probes and therapeutic agents. Our new method, recently reported in Nature Chemistry, provides a solution to this challenge. Paraza Pharma and Genentech are the two partner organizations on this application.Genentech is a large biotechnology company with a rich history of excellence in peptide science and peptide-based drugs. Genentech Inc. has invested in the Yudin group as an industry partner with the goal to advance the understanding of peptide science. Genentech Inc. aims to use the technology developed in the Yudin lab to access new tools towards the synthesis of conformationally-controlled peptide-based inhibitors of protein-protein interactions. Genentech's involvement would help the Yudin lab to develop a library of structurally diverse macrocycles with unique dominant rotor sub-structures, and assess their chemical, physical, and biological properties in a much shorter amount of time compared to what is typically expected in an academic setting. Paraza Pharma is a chemical sciences-based company with aims towards streamlining the drug discovery processes. The company will use Yudin's chemistry in order to incorporate imidazopyridines into dominant rotors, deploy their exciting benzocyclobutane amino acids, and guide us through construction of macrocyclic kinase inhibitors. Paraza will provide scientific expertise in process and analytical development, particularly with regard to the suitability of Yudin's building blocks in synthesis.
Program
Alliance Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
565585-2021
Name nom
Yudin, Andrei
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2021
Award amount
65500
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Installment
inst:1
Partie
1
Nb partie
1
Application title
Development of the Dominant Rotor Technology for Drug Discovery
Keyword
NSERC
Application summary
This proposal leverages the recently developed technology aimed at conformation-activity studies and rarely visited conformations of complex rings. The primary focus is on macrocycles that are primarily composed of natural amino acid building blocks. While cyclic peptides have received a tremendous amount of attention over the years, their structures are not ideally suited for the development of biological probes and therapeutic agents. Our new method, recently reported in Nature Chemistry, provides a solution to this challenge. Paraza Pharma and Genentech are the two partner organizations on this application.Genentech is a large biotechnology company with a rich history of excellence in peptide science and peptide-based drugs. Genentech Inc. has invested in the Yudin group as an industry partner with the goal to advance the understanding of peptide science. Genentech Inc. aims to use the technology developed in the Yudin lab to access new tools towards the synthesis of conformationally-controlled peptide-based inhibitors of protein-protein interactions. Genentech's involvement would help the Yudin lab to develop a library of structurally diverse macrocycles with unique dominant rotor sub-structures, and assess their chemical, physical, and biological properties in a much shorter amount of time compared to what is typically expected in an academic setting. Paraza Pharma is a chemical sciences-based company with aims towards streamlining the drug discovery processes. The company will use Yudin's chemistry in order to incorporate imidazopyridines into dominant rotors, deploy their exciting benzocyclobutane amino acids, and guide us through construction of macrocyclic kinase inhibitors. Paraza will provide scientific expertise in process and analytical development, particularly with regard to the suitability of Yudin's building blocks in synthesis.